Needle Free and Alternative Administration Patents: Top Companies 2026
Needle Free and Alternative Administration Patents: Who Leads and Where the Gaps Sit
One leader, a long tail. The top assignee holds 29 families against a fifth-place count of 12 and a tenth-place count of 4, across 34 ranked companies. Filings ran at 15 in 2017 and rose to a peak of 19 in 2019 before easing back. The tracked growth figure of 2021's 8 filings falling to 2024's 3 — a -63% move — is the most recent span that can be read as a real slowdown rather than a publication-lag artefact; 2025 and 2026 will fill in as later filings publish.
- 1RAMOT AT TEL AVIV UNIVERSITY LTD29
- 2ALLERGAN INC22
- 3ENZYSURGE18
- 4VAXXAS PTY LTD14
- 5TRANSDERM12
See the full needle free and alternative administration analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in needle-free and alternative drug administration?
The ranked leader in this 133-record corpus holds 29 families, well ahead of the fifth-ranked company at 12 and the tenth-ranked company at 4, across a ranking of 34 companies total. That said, the leader shows no filings in the latest tracked year, which suggests an early filing push rather than an actively growing position. Anyone assessing freedom to operate should look at the leader’s actual claim scope rather than assuming raw family count equals current market control.
Is patent filing activity in this field growing or slowing down?
Filings peaked at 19 in 2019 and the most recent complete comparison, 2021’s 8 filings against 2024’s 3, shows a -63% move. However, publication lags filing by roughly 18 months, so 2025 and 2026 figures are still incomplete and should not be read as continuing evidence of decline. The honest read is that activity has cooled from its 2019 high, with the true 2025-2026 picture not yet visible.
What technology areas dominate microneedle and needle-free delivery patents?
A61M, covering devices for body fluids, appears in 66.9% of the 133 records in scope, and A61K, covering medicinal preparations, appears in 51.9%. Because a single record can carry multiple IPC classes, many filings combine a delivery-device claim with a formulation claim in the same document. Diagnosis and surgery (A61B), genetic engineering (C12N) and therapeutic activity (A61P) classes are present but noticeably thinner, and electrotherapy, physical therapy and animal husbandry applications remain narrow niches under 7% each.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Needle Free and Alternative Administration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.